Author:
Negru Serban,Papadopoulou Eirini,Apessos Angela,Stanculeanu Dana Lucia,Ciuleanu Eliade,Volovat Constantin,Croitoru Adina,Kakolyris Stylianos,Aravantinos Gerasimos,Ziras Nikolaos,Athanasiadis Elias,Touroutoglou Nikolaos,Pavlidis Nikolaos,Kalofonos Haralabos P,Nasioulas George
Reference24 articles.
1. NRAS mutations are rare in colorectal cancer;Irahara;Diagn Mol Pathol,2010
2. Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR;Heinemann;Cancer Treat Rev,2009
3. Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer;Vaughn;Genes Chromosomes Cancer,2011
4. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis;De Roock;Lancet Oncol,2010
5. Single agent panitumumab in KRAS wild-type metastatic colorectal cancer patients following cetuximab-based regimens: clinical outcome and biomarkers of efficacy;Pietrantonio;Cancer Biol Ther,2013
Cited by
28 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献